N@N

China Aoxing Pharmaceutical Co., Inc.: China Aoxing Pharmaceutical Company Enters Agreement to Divest Non-Core Land Property

_{//health-fitness.news-articles.net/content/2009/ .. -agreement-to-divest-non-core-land-property.html}
^{Published in Health and Fitness on Monday, May 18th 2009 at 5:34 GMT, Last Modified on 2009-11-02 12:21:20 by Market Wire}  

NEW YORK, NY--(Marketwire - May 18, 2009) - China Aoxing Pharmaceutical Company, Inc. (OTCBB: [ CAXG ]) ("China Aoxing"), a pharmaceutical company specializing in research, development, manufacturing and marketing of narcotic and pain-management products, today announced that it has entered into a definitive agreement to sell its non-core land property at 33 million RMB, or approximately $4.8 million, in cash. The sale is expected to close, subject to regulatory review, by June 15, 2009. China Aoxing will use proceeds from the sale for general corporate purposes.

"Divesting the non-core land property is an important milestone in our strategy to focus on core pharmaceutical business and to strength our balance sheet by rationalizing non-essential assets through a non-dilutive transaction to our shareholders. This sale was carefully considered by the Board of Directors and based on a number of business reasons," said Juan Yue Han, Chairman and the CEO of China Aoxing, "A sharper strategic focus can facilitate business growth and potential for achieving further operating efficiencies, accelerating our timeline to profitability."

Under the terms of the divestiture agreement, the land property to be divested occupies 18,350 square meters (or 197,518 square foot, or 4.53 acres) located at the manufacuring facility of Shijazhuang Lerentang Pharmaceutical Company, Ltd. ("LRT"), an operational subsidiary of China Aoxing. The property becomes no longer essential to Company operations as LRT business is fully integrated into Hebei Aoxing. The transaction was conducted in a publicized auction at Shijiazhuang City and the property was sold to the highest joint bidders from Hebei Xinxing Geli Electronics Marketing Company Ltd and Shijiazhuang City Xinyang Weiye Property Company, Ltd., PRC companies.

This transaction is not associated with the land property of Hebei Aoxing, the main campus of China Aoxing, which occupies 200,000 square meters (or 49 acres) and is sufficient to support its business expansion in foreseeable future.

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: [ CAXG ]) is a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. It has a strategic alliance with American Oriental Bioengineering, Inc. (NYSE: [ AOB ]) to develop and market various narcotic drugs in China. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, China Aoxing has China's largest and the most advanced manufacturing facility for highly regulated narcotic medicines, addressing a very under-served and fast- growing market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-KSB for the year ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.